Head & Neck Cancers | Specialty

Novel NGS Test May Enhance Diagnosis and Management of Indeterminate Thyroid Nodules

November 2nd 2014

A next-generation sequencing assay has shown promise as a new tool to aid in the diagnosis and treatment of indeterminate thyroid nodules.

Next-Generation Sequencing Effectively Detects Cancer in Thyroid Nodules

November 2nd 2014

The ThyroSeq v2 next-generation sequencing assay was highly accurate at diagnosing cancer in thyroid nodules with follicular neoplasm or those suspected of follicular neoplasm cytology.

Vitamin D Levels Predict Hypocalcemia After Thyroid Cancer Treatment

November 1st 2014

Preoperative vitamin D deficiency is associated with postoperative symptomatic hypocalcemia in patients with thyroid cancer undergoing total thyroidectomy plus central compartment neck dissection.

Novel Therapeutic Target Identified in Aggressive Thyroid Cancers

November 1st 2014

In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with β-aminopropionitrile fumarate.

New Assay Effectively Detects Circulating BRAFV600E in Patients With Papillary Thyroid Cancer

November 1st 2014

The detection of BRAFV600E in patients with papillary thyroid cancer using a blood-based assay was shown to be feasible in a cohort of patients undergoing thyroidectomy.

Dr. Ganly on a Postoperative Nomogram for Predicting Cancer-Specific Mortality in MTC

November 1st 2014

Ian Ganly, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses the development of a postoperative nomogram for predicting cancer-specific mortality in MTC.

Dr. Bible Discusses the Promise of Pemetrexed in Follicular Thyroid Cancers

November 1st 2014

Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the promise of pemetrexed and carboplatin as a potential treatment option for patients with follicular cell-derived thyroid cancers.

ATA Highlights New Thyroid Cancer Research

October 31st 2014

The impact of RAI on long-term outcomes, potential combination strategies, molecular profiling, and novel therapeutics for patients with thyroid cancer were among some of the topics highlighted at the 2014 ATA Annual Meeting.

Dr. Busaidy on the Association Between THST and Improved Outcomes

October 31st 2014

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.

Moderate THST Improves Outcomes in Differentiated Thyroid Cancer

October 31st 2014

Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in patients with differentiated thyroid cancer.

Dr. Nucera Discusses the Role of RNA in Thyroid Cancer

October 31st 2014

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

Disease-Related Variables Predictive of Outcomes With Sorafenib in DTC

October 31st 2014

Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.

Dr. Dadu on Reducing MTC-Related Diarrhea With CASAD

October 31st 2014

Ramona Dadu, MD, from the MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of CASAD, a natural clay, to reduce medullary thyroid cancer-related diarrhea.

Dr. Cohen Discusses the Challenges of Treating Medullary Thyroid Cancer

October 30th 2014

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the challenges of treating Medullary Thyroid Cancer (MTC).

Molecular Diagnostics Focus on Thyroid Nodule Classification

October 30th 2014

New data being presented at the 84th Annual Meeting of the American Thyroid Association show promise for two molecular tests that help identify indeterminate thyroid nodules as either benign or malignant.

Latest News & Insight: October 27, 2014

October 27th 2014

Lenvatinib Receives Priority Review for RAI-Refractory DTC

October 17th 2014

The FDA has granted a priority review to the oral multiple tyrosine kinase receptor inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), according to the manufacturer of the drug, Eisai.

Afatinib Improves PFS and Quality of Life in Advanced HNSCC

September 27th 2014

Afatinib delayed disease progression for approximately one month longer than chemotherapy and helped prevent painful symptoms from worsening for patients with relapsed or metastatic head and neck squamous cell carcinoma.

Radiotherapy Without Chemo Can Ease Dysphagia in Patients With Advanced Esophageal Cancer

September 15th 2014

Radiotherapy is equally as effective in the palliation of dysphagia (difficulty swallowing) as chemoradiotherapy for patients with advanced esophageal cancer

FDA Approval Sought for Lenvatinib in Differentiated Thyroid Cancer

August 31st 2014

Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting.